Published a collaborative research paper, led by RIKEN, on the potential of anti-TMPRSS2 antibody therapy.

Scientists have developed monoclonal antibodies (mAbs) that target TMPRSS2, a protein on human cells that helps the coronavirus (SARS-CoV-2) enter the body. These antibodies were able to block infection in laboratory-grown cells and human lung organoids, and they worked against all tested variants, including Omicron. Instead of shutting down the protein’s normal enzyme activity, the antibodies seem to block the virus from physically interacting with the cell entry system. In studies with specially engineered mice and macaques, the treatment reduced the amount of virus in the lungs and eased inflammation, showing promising effects as a potential COVID-19 therapy.

Harada M et al. Monoclonal antibodies against human TMPRSS2 prevent infection by any SARS-CoV-2 variant. iScinece. 28:113424, 2025.